ClinicalTrials.gg
RecruitingNCT06298565Updated Nov 16, 2026

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

An observational study in Myasthenia Gravis, sponsored by argenx. Recruiting at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by argenx · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 16, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
680
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Myasthenia Gravis by argenx — 9 open to participants now, 12 under way, 5 of them phase 3. Myasthenia Gravis · argenx.

Started
2024
with 3 others
Observational
4 of 18
4 open now
Primary completion
2034-06
later than 11 of 11 live
Registered
10th of 18
by date

Among the 18 studies in Myasthenia Gravis by argenx, this one is one of 4 that started in 2024, is one of 4 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 10th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

9 of the 18 studies in Myasthenia Gravis by argenx are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Myasthenia Gravis by argenx, or all of them as a file.
02

Study summary

This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with gMG

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment
  • Have provided appropriate written

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
680 participants (estimated)
Patient registry
No

Groups and cohorts

  • efgartigimod cohort

    patients treated with efgartigimod

    Biological: efgartigimod

  • non-efgartigimod cohort

    patient treated with other MG medication

Interventions

06

What researchers measure

Primary outcomes

  1. The overall long-term safety of efgartigimod including the occurrence of serious infections in generalized myasthenia gravis (gMG) patients treated with efgartigimod compared to gMG patients not exposed to efgartigimod

    Time frame: up to 10 years

07

Study locations

36 of 36 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2034, 115 months after the start.

Of 62 observational studies under Myasthenia Gravis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24. This study's planned 115 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Nov 4, 2024
Primary completionEst.
Jun 2034
CompletionEst.
Jun 2034
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • ASST Papa Giovanni XXIII · Bergamo, Italy
Nov 16, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • UZ Leuven (University Hospitals Leuven) · Leuven, BelgiumContact c•••@argenx.com→k•••@uzleuven.be
  • Ospedale Bellaria - Clinica Neurologica · Bologna, ItalyContact •••4834→•••4400Contact c•••@argenx.com→m•••@ausl.bologna.it
  • Azienda Ospedaliera di Rilievo Nazionale Cardarelli · Naples, ItalyContact •••4834→•••3087Contact c•••@argenx.com→f•••@aocardarelli.it
  • Azienda Ospedaliero Universitaria Pisana · Pisa, ItalyContact •••4834→•••2088Contact c•••@argenx.com→m•••@gmail.com
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added
    Show site
    • ASST Papa Giovanni XXIII · Bergamo, Italy
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • UZ Leuven (University Hospitals Leuven) · Leuven, BelgiumContact c•••@argenx.com→k•••@uzleuven.be
    • Ospedale Bellaria - Clinica Neurologica · Bologna, ItalyContact •••4834→•••4400Contact c•••@argenx.com→m•••@ausl.bologna.it
    • Azienda Ospedaliera di Rilievo Nazionale Cardarelli · Naples, ItalyContact •••4834→•••3087Contact c•••@argenx.com→f•••@aocardarelli.it
    • Azienda Ospedaliero Universitaria Pisana · Pisa, ItalyContact •••4834→•••2088Contact c•••@argenx.com→m•••@gmail.com

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06298565
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Nov 4, 2024
Primary completion
Jun 2034 (estimated)
Completion
Jun 2034 (estimated)
Last update
Nov 16, 2026

Study contacts

Sabine Coppieters, MD
Contact
Clinicaltrials@argenx.com
857-350-4834

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion